I also liked the fact that the CKD trial would be able to piggy back to an extent on the organisation already done for the FSGS trial - should reduce costs and facilitate earlier results.
Ann: Half Year Report and Financial Statements, page-59
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.3¢ |
Change
-0.018(4.73%) |
Mkt cap ! $25.68M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.0¢ | 35.3¢ | $404.7K | 1.116M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 149218 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 51186 | 6 |
View Market Depth
| Last trade - 12.31pm 05/12/2024 (20 minute delay) ? |
| DXB (ASX) Chart |